← Back to Clinical Trials
Recruiting NCT07079592

NCT07079592 A Deep-Learning-Enabled Electrocardiogram for Detecting Pulmonary Hypertension

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07079592
Status Recruiting
Phase
Sponsor National Defense Medical Center, Taiwan
Condition Artificial Intelligence (AI)
Study Type INTERVENTIONAL
Enrollment 8,666 participants
Start Date 2026-02
Primary Completion 2026-06-15

Eligibility & Interventions

Sex All sexes
Min Age 50 Years
Max Age 85 Years
Study Type INTERVENTIONAL
Interventions
AI-ECG Guidance

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 8,666 participants in total. It began in 2026-02 with a primary completion date of 2026-06-15.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

This study aims to validate the use of an artificial intelligence-enabled electrocardiogram (AI-ECG) to screen for elevated PAP. We hypothesize that the AI-ECG model can early identify patients with pulmonary hypertension in high-risk patients, prompting further evaluation through echocardiography, potentially resulting in improving cardiovascular outcomes.

Eligibility Criteria

Inclusion Criteria: * Men or women, ≥ 50 to 85 years of age * At least one 12-lead ECG within 3 months Exclusion Criteria: * A diagnosis of PH WHO Groups 1, 2, 3, 4, or 5 * A diagnosis of hypertrophic cardiomyopathy, restrictive cardiomyopathy, constrictive pericarditis, cardiac amyloidosis, or infiltrative cardiomyopathy * Prior heart, lung, or heart-lung transplants * Any systolic pulmonary artery pressure \>50 mmHg by echocardiography before * Echocardiography in 3 months before index ECG

Contact & Investigator

Central Contact

Chin Lin, Associate Professor

✉ up6fup0629@gmail.com

📞 886+2-87923311

Principal Investigator

Chin Lin, associate professor

STUDY DIRECTOR

National Defense Medical Center, Taiwan

Frequently Asked Questions

Who can join the NCT07079592 clinical trial?

This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Artificial Intelligence (AI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT07079592 currently recruiting?

Yes, NCT07079592 is actively recruiting participants. Contact the research team at up6fup0629@gmail.com for enrollment information.

Where is the NCT07079592 trial being conducted?

This trial is being conducted at Taipei, Taiwan.

Who is sponsoring the NCT07079592 clinical trial?

NCT07079592 is sponsored by National Defense Medical Center, Taiwan. The principal investigator is Chin Lin, associate professor at National Defense Medical Center, Taiwan. The trial plans to enroll 8,666 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology